217 related articles for article (PubMed ID: 31735362)
21. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
22. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.
Turner DC; Kondic AG; Anderson KM; Robinson AG; Garon EB; Riess JW; Jain L; Mayawala K; Kang J; Ebbinghaus SW; Sinha V; de Alwis DP; Stone JA
Clin Cancer Res; 2018 Dec; 24(23):5841-5849. PubMed ID: 29891725
[TBL] [Abstract][Full Text] [Related]
24. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
25. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
26. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
Marur S; Singh H; Mishra-Kalyani P; Larkins E; Keegan P; Sridhara R; Blumenthal GM; Pazdur R
Semin Oncol; 2018 Aug; 45(4):220-225. PubMed ID: 30391014
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
Dudnik E; Moskovitz M; Daher S; Shamai S; Hanovich E; Grubstein A; Shochat T; Wollner M; Bar J; Merimsky O; Zer A; Goldstein DA; Hammerman A; Cyjon A; Shechtman Y; Abu-Amna M; Flex D; Roisman LC; Peled N;
Lung Cancer; 2018 Dec; 126():217-223. PubMed ID: 29254746
[TBL] [Abstract][Full Text] [Related]
28. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
[TBL] [Abstract][Full Text] [Related]
29. CT based radiomic approach on first line pembrolizumab in lung cancer.
Zerunian M; Caruso D; Zucchelli A; Polici M; Capalbo C; Filetti M; Mazzuca F; Marchetti P; Laghi A
Sci Rep; 2021 Mar; 11(1):6633. PubMed ID: 33758304
[TBL] [Abstract][Full Text] [Related]
30. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
31. Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients.
Katayama Y; Yamada T; Chihara Y; Tanaka S; Tanimura K; Okura N; Hirose K; Uda S; Shiotsu S; Hirai S; Hiranuma O; Harada T; Shimamoto T; Iwasaku M; Kaneko Y; Uchino J; Takeda T; Takayama K
Sci Rep; 2020 Oct; 10(1):17495. PubMed ID: 33060826
[TBL] [Abstract][Full Text] [Related]
32. Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.
Gandara DR; von Pawel J; Mazieres J; Sullivan R; Helland Å; Han JY; Ponce Aix S; Rittmeyer A; Barlesi F; Kubo T; Park K; Goldschmidt J; Gandhi M; Yun C; Yu W; Matheny C; He P; Sandler A; Ballinger M; Fehrenbacher L
J Thorac Oncol; 2018 Dec; 13(12):1906-1918. PubMed ID: 30217492
[TBL] [Abstract][Full Text] [Related]
33. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
Berardi R; Rinaldi S; Santoni M; Newsom-Davis T; Tiberi M; Morgese F; Caramanti M; Savini A; Ferrini C; Torniai M; Fiordoliva I; Bower M; Cascinu S
Oncotarget; 2016 May; 7(18):26916-24. PubMed ID: 27029035
[TBL] [Abstract][Full Text] [Related]
34. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
Ahn BC; Pyo KH; Xin CF; Jung D; Shim HS; Lee CY; Park SY; Yoon HI; Hong MH; Cho BC; Kim HR
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1613-1623. PubMed ID: 30911841
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
38. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
Chalabi M; Cardona A; Nagarkar DR; Dhawahir Scala A; Gandara DR; Rittmeyer A; Albert ML; Powles T; Kok M; Herrera FG;
Ann Oncol; 2020 Apr; 31(4):525-531. PubMed ID: 32115349
[TBL] [Abstract][Full Text] [Related]
40. bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer.
Fan Y; Liu Y; Wang L; Cai Y; Cao W; Sun W; Zou X; Li B; Zhang Z; Cai S; Chuai S; Han Y; Pan X; Huang D
EBioMedicine; 2023 May; 91():104564. PubMed ID: 37094467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
